INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Spectrum Pharmaceuticals, Inc.

Goldberg Law PC announces that it is investigating Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (Nasdaq: SPPI) concerning possible violations of federal securities laws.

If you purchased or otherwise acquired Spectrum shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at [e-mail].

The investigation focuses on a statement by the Company that it failed to disclose that the Food & Drug Administration advised it to not submit a New Drug Application for its drug candidate apaziquone back in December of 2012.

If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at [e-mail].

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160916005873/en/

Goldberg Law PC, Los AngelesMichael Goldberg, Esq., 800-977-7401Brian Schall, Esq., [e-mail]://www.Goldberglawpc.com